CUV clinuvel pharmaceuticals limited

Ann: CLINUVEL Unveils Vitiligo Program for AAD 2025, page-51

  1. 1,551 Posts.
    lightbulb Created with Sketch. 163
    My bad, appears to be true, but no reimbursement.

    AVH.....

    Following FDA approval, we conducted a post-market study and initiated a health economics study to capture the
    longitudinal healthcare costs for a vitiligo patient. Both studies were submitted for publication in 2024. In early 2025, we expect these
    studies to be published, which will support the possible reimbursement necessary for the commercialization of the vitiligo indication
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$9.83
Change
0.000(0.00%)
Mkt cap ! $496.2M
Open High Low Value Volume
$9.89 $9.99 $9.66 $441.6K 44.96K

Buyers (Bids)

No. Vol. Price($)
5 124 $9.83
 

Sellers (Offers)

Price($) Vol. No.
$9.85 111 9
View Market Depth
Last trade - 12.16pm 16/06/2025 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.